H.C. Wainwright analyst Andrew Fein lowered the firm’s price target on Neurocrine (NBIX) to $168 from $185 and keeps a Buy rating on the ...

H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on uniQure (QURE – Research Report) on April 17 and set a price target of ...

Insights from analysts' 12-month price targets are revealed, presenting an average target of $17.08, a high estimate of ...

Richtech Robotics ( NASDAQ: RR) rallied in late Friday morning trading after H.C. Wainwright initiated coverage on the stock with a Buy rating.

Across the recent three months, 11 analysts have shared their insights on argenx ARGX + Free Alerts , expressing a variety of ...

Fintel reports that on April 11, 2025, HC Wainwright & Co. initiated coverage of Richtech Robotics (NasdaqCM:RR) with a Buy ...

Fintel reports that on April 10, 2025, HC Wainwright & Co. downgraded their outlook for Tempest Therapeutics (NasdaqCM:TPST) ...

Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for ...

H.C. Wainwright analyst Patrick Trucchio initiated coverage of Alto Neuroscience (ANRO) with a Buy rating and $10 price target Alto is redefining neuropsychiatric drug development through the ...

HC Wainwright analyst A. Fein now forecasts that the company will post earnings of ($3.56) per share for the quarter, down from their previous estimate of ($0.86).